Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 61 to 70 of 93 total matches.
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only) ...
On April 13, 2021, the FDA and CDC advised suspending
use of the Johnson & Johnson adenovirus-based
COVID-19 vaccine while the agencies investigate 6
cases of cerebral venous sinus thrombosis (CVST) and
thrombocytopenia that occurred following administration
of the vaccine. In an April 14 emergency meeting,
the Advisory Committee on Immunization Practices
(ACIP) recommended continuing the suspension until
more data become available. About 7 million people in
the US have received the Johnson & Johnson vaccine.
COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld) ...
The labeling for the investigational, long-acting,
prophylactic anti-SARS-CoV-2 monoclonal antibodies
tixagevimab and cilgavimab (Evusheld; available under
an FDA Emergency Use Authorization) now includes
warnings about a risk of serious hypersensitivity
reactions, including anaphylaxis, with use of the
drugs, particularly in patients who have experienced a
hypersensitivity reaction to a COVID-19 vaccine.
COVID-19 Update: Prescription of Paxlovid by Pharmacists (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
COVID-19 Update: Prescription of Paxlovid by Pharmacists (online only) ...
The FDA has amended its Emergency Use Authorization (EUA) for Paxlovid (Pfizer), the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir, to allow for it to be prescribed by licensed pharmacists in certain situations. Paxlovid is authorized for oral treatment of mild to moderate COVID-19 in high-risk outpatients ≥12 years old who weigh at least 40 kg. NIH guidelines list it as the treatment of choice for COVID-19 in high-risk adult outpatients.
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only) ...
View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e1 doi:10.58347/tml.2023.1687e | Show Introduction Hide Introduction
COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (online only) ...
The FDA has amended its Emergency Use
Authorization (EUA) for the investigational long-acting
monoclonal antibodies tixagevimab and
cilgavimab (Evusheld – AstraZeneca) to recommend
repeat dosing every 6 months in patients who require
ongoing protection against COVID-19. Evusheld
is authorized for IM pre-exposure prophylaxis of
COVID-19 in persons ≥12 years old who weigh ≥40 kg
and have either a history of a severe adverse reaction
that prevents their vaccination against COVID-19 or
moderate or severe immune compromise
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old ...
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
Treatment of COVID-19 in High-Risk Outpatients (online only)
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022 (Issue 1643)
Treatment of COVID-19 in High-Risk Outpatients (online only) ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Correction
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
Correction
In our article in issue 1687 on the updated 2023-2024 COVID-19
vaccines from Pfizer ...
In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines
from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161),
the doses and formulations of the Pfizer vaccine were incorrect. A
revised table has been posted in the online version of the article.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):184 doi:10.58347/tml.2023.1689d | Show Introduction Hide Introduction
Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines (online only) ...
View the Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1 doi:10.58347/tml.2023.1675g | Show Introduction Hide Introduction
Ponesimod (Ponvory) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
.
COVID-19 — Use of disease-modifying therapy for
treatment of MS has not been associated ...
The FDA has approved ponesimod (Ponvory –
Janssen), a sphingosine 1-phosphate (S1P) receptor
modulator, for treatment of adults with relapsing forms
of multiple sclerosis (MS), including clinically isolated
syndrome (initial neurological episode), relapsing-remitting
disease, and active secondary progressive
MS (SPMS). Ponesimod is the fourth oral S1P receptor
modulator to be approved in the US for once-daily
treatment of relapsing forms of MS; ozanimod
(Zeposia) and siponimod (Mayzent) are also approved
for use in adults, and fingolimod (Gilenya) is indicated
for use in patients...